Suppr超能文献

实验性心脏移植模型中移植血管硬化的发病机制与预防

Pathogenesis and prevention of graft arteriosclerosis in an experimental heart transplant model.

作者信息

Lurie K G, Billingham M E, Jamieson S W, Harrison D C, Reitz B A

出版信息

Transplantation. 1981 Jan;31(1):41-7. doi: 10.1097/00007890-198101000-00010.

Abstract

Accelerated graft arteriosclerosis is a major cause of death in human heart transplantation. Despite many investigations, the pathogenesis of this disease remains undetermined and its control inadequate. In this study using a rat heart transplant model and cyclosporin A, a new immunosuppressant, acute rejection was prevented but arteriosclerotic-like vessel disease still developed consistently as early as 20 days postoperatively. The combination of cyclosporin A and dipyridamole prevented the development of this vessel disease in transplanted hearts at 20 and 50 days postoperatively. Sulfinpyrazone and cyclosporin A reduced but did not prevent the disease. These findings suggest that immunologically induced graft arteriosclerosis can be prevented in transplanted rat hearts by the combination of cyclosporin A and dipyridamole.

摘要

加速性移植血管硬化是人类心脏移植死亡的主要原因。尽管进行了许多研究,但这种疾病的发病机制仍未明确,对其控制也不完善。在本研究中,使用大鼠心脏移植模型和新型免疫抑制剂环孢素A,可预防急性排斥反应,但早在术后20天就会持续出现类似动脉硬化的血管疾病。环孢素A和双嘧达莫联合使用可在术后20天和50天时预防移植心脏出现这种血管疾病。磺吡酮和环孢素A可减轻但不能预防该疾病。这些发现表明,环孢素A和双嘧达莫联合使用可预防移植大鼠心脏中免疫诱导的移植血管硬化。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验